Phase 3 Trial of Acalabrutinib in Combination with Venetoclax, With and Without Obinutuzumab Versus Chemoimmunotherapy for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

被引：0
|
作者：
Brown, Jennifer R. [1 ]
Eichhorst, Barbara [2 ]
Ghia, Paolo [3 ,4 ]
Kater, A. P. [5 ]
Li, Jianyong [6 ]
Khurana, Sudha [7 ]
Elhamy, Mostafa [7 ]
Wang, Min Hui [7 ]
Seymour, John F. [8 ,9 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Univ Hosp Cologne, Cologne, Germany
[3] Univ Vita Salute Raffaele, Milan, Italy
[4] IRCCS Osped San Raffaele, Milan, Italy
[5] Amsterdam UMC, Amsterdam, Netherlands
[6] Nanjing Med Univ, Affiliated Hosp 1, Jiansu Sheng, Peoples R China
[7] Acerta Pharma, San Francisco, CA USA
[8] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[9] Royal Melbourne Hosp, Melbourne, Vic, Australia
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2020年 / 20卷
关键词：
CLL; chronic lymphocytic leukemia; acalabrutinib; Bruton tyrosine kinase inhibitor; combination therapy;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CLL-092
引用
收藏
页码：S221 / S222
页数：2
相关论文
共 50 条
  • [1] MAJIC: a phase III trial of acalabrutinib plus venetoclax versus venetoclax plus obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma
    Ryan, Christine E.
    Davids, Matthew S.
    Hermann, Richard
    Shahkarami, Mina
    Biondo, Juliana
    Abhyankar, Sarang
    Alhasani, Hasan
    Sharman, Jeff P.
    Mato, Anthony R.
    Roeker, Lindsey E.
    FUTURE ONCOLOGY, 2022, 18 (33) : 3689 - 3699
  • [2] MAJIC: a phase III trial of acalabrutinib + venetoclax versus venetoclax + obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma (vol 18, pg 3689, 2022)
    Ryan, Christine E.
    Davids, Matthew S.
    Hermann, Richard
    Shahkarami, Mina
    Biondo, Juliana
    Abhyankar, Sarang
    Alhasani, Hasan
    Sharman, Jeff P.
    Mato, Anthony R.
    Roeker, Lindsey E.
    FUTURE ONCOLOGY, 2023,
  • [3] A Phase 3 Trial Comparing the Efficacy and Safety of Acalabrutinib in Combination with Venetoclax with or without Obinutuzumab, Compared with Investigator's Choice of Chemoimmunotherapy in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) without Del(17p) or TP53 Mutation
    Brown, Jennifer R.
    Eichhorst, Barbara F.
    Ghia, Paolo
    Kater, Arnon P.
    Li, Jianyong
    Khurana, Sudha
    Elhamy, Mostafa
    Wang, Min Hui
    Seymour, John F.
    BLOOD, 2019, 134
  • [4] Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL)
    Lampson, Benjamin L.
    Tyekucheva, Svitlana
    Crombie, Jennifer L.
    Kim, Austin I.
    Merryman, Reid W.
    Lowney, Jessica
    Montegaard, Josie
    Patterson, Victoria
    Jacobson, Caron A.
    Jacobsen, Eric D.
    LaCasce, Ann S.
    Arnason, Jon E.
    Armand, Philippe
    Fisher, David C.
    Brown, Jennifer R.
    Davids, Matthew S.
    BLOOD, 2019, 134
  • [5] Majic: A Phase 3 Prospective, Multicenter, Randomized, Open-Label Trial of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
    Davids, Matthew S.
    Mato, Anthony R.
    Hum, Juliette
    Wargo, Susana
    Emeribe, Ugochinyere
    Shahkarami, Mina
    Sokolowski, Kevin
    Biondo, Juliana M. L.
    Abhyankar, Sarang
    Hermann, Rick
    Sharman, Jeff P.
    BLOOD, 2021, 138
  • [6] Cost-effectiveness of acalabrutinib monotherapy or with obinutuzumab versus chemoimmunotherapy for untreated chronic lymphocytic leukemia in China
    Li, Mengya
    Zhong, Xiaoyan
    Zhang, Chengbin
    Luo, Hongli
    Luo, Li
    Huang, Yilan
    Jiang, Longyang
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2024, 15
  • [7] Elevate Tn Phase 3 Study of Acalabrutinib Plus Obinutuzumab or Acalabrutinib Monotherapy vs Chlorambucil Plus Obinutuzumab (ClbO) in Subjects with Previously Untreated Chronic Lymphocytic Leukemia (CLL)
    Martens, Uwe
    Sharman, Jeff
    Banerji, Versha
    Fogliatto, Laura Maria
    Herishanus, Yair
    Munir, Talha
    Walewska, Renato
    Follows, George
    Karlsson, Karin
    Ghia, Paolo
    Corbett, Gillian
    Walker, Patricia
    Egyed, Miklos
    Jurczak, Wojciech
    Salles, Gilles
    Janssens, Ann
    Cymbalista, Florence
    Wierda, William
    Coutre, Steven E.
    Pagel, John M.
    Skarbnik, Alan P.
    Kamdar, Manali
    Izumi, Raquel
    Munugala, Veerendra
    Patel, Priti
    Wang, Min Hui
    Wong, Sofia
    Woyach, Jennifer
    Byrd, John
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 127 - 127
  • [8] Prospective Randomized Phase 2 Study of Acalabrutinib plus Obinutuzumab or Venetoclax in Previously Untreated CLL
    Kittai, Adam S.
    Huang, Ying
    Bhat, Seema A.
    Grever, Michael R.
    Suresh, Swetha
    Lozanski, Gerard
    Moran, Mollie
    Nussbaum, Megan
    Woyach, Jennifer A.
    Rogers, Kerry A.
    BLOOD, 2024, 144
  • [9] Preliminary Safety and Efficacy Results From a Phase 2 Study of Acalabrutinib, Venetoclax, and Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia
    Awan, Farrukh T.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (01) : 6 - 8
  • [10] ACALABRUTINIB (AKA) VERSUS VENETOCLAX WITH OBINUTUZUMAB (VEN plus OBI) IN PATIENTS WITH UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND UNMUTATED IGHV GENES - INDIRECT COMPARISON
    Kaczynski, L.
    Kowal, P.
    Wojcik, R.
    Kaczor, M. P.
    VALUE IN HEALTH, 2023, 26 (12) : S39 - S39
12345